By vgreene, 4 March, 2021 Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID 19 Pneumonia A Randomized Clinical Trial
By vgreene, 4 March, 2021 Study considerations randomized but open label primary outcome amended mid study small sample size usual care not standardized earlier TCZ admin not evaluated CS used more in usual care group
By vgreene, 4 March, 2021 KEY FINDINGS Compared w usual care TCZ did not decr dz progression at day 4 or death at day 28 but may reduce risk of ventilation death at day 14
By vgreene, 4 March, 2021 Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID 19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
By vgreene, 4 March, 2021 Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID 19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
By vgreene, 4 March, 2021 No significant difference in 28 day clinical status TCZ 1 0 vs placebo 2 0 on 7 category ordinal scale or mortality TCZ 19 7 placebo 19 4 similar rates of adverse events in both groups
